News Sentiment

DMAC sentiment intelligence

DiaMedica Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.30 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-4.8% over one week, +24.8% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -4.8% Price reacting lower
Trend fit Trend inactive 24.8% over four weeks
Fair value 53.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 35
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 8
MarketBeat 5
TradingView 5
Business Wire 3
Moomoo 3
MT Newswires 3
TradingKey 3

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 17
Analyst action 3
Guidance 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54
Stock Titan Direct company coverage

Stroke and preeclampsia biotech DiaMedica joins New York healthcare conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focusing on treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, announced its presentation at the 2026 Jefferies Global Healthcare Conference in New York. The comp

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 03:39
Source
Stock Titan
Stock Titan Direct company coverage

DiaMedica Therapeutics (DMAC) director receives 40,412-share stock option grant

DiaMedica Therapeutics Inc. director Charles Pauling Semba was granted options for 40,412 shares of Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036. These options are scheduled to vest in four equal quarterly installments. This grant is cons

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 01:10
Source
Stock Titan
Stock Titan Direct company coverage

DiaMedica (DMAC) director Richard Kuntz receives grant of 40,412 stock options

DiaMedica Therapeutics Inc. director Richard Kuntz was granted 40,412 stock options with an exercise price of $5.84 per share, expiring on June 1, 2036. These options vest in four equal quarterly installments. Following this transaction, Kuntz directly holds 40,412 derivative sec

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

DiaMedica Therapeutics (DMAC) CEO awarded 380,000 stock options

DiaMedica Therapeutics (DMAC) CEO Dietrich John Pauls was granted 380,000 stock options as compensation, not an open-market trade. The options have an exercise price of $5.84 per share and expire on June 1, 2036. These options will vest 25% on the one-year anniversary of the gran

Tone
Positive 59/100
Event
Market update
Published
03 Jun 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

DiaMedica Therapeutics (DMAC) CFO awarded 162,000 stock options at $5.84 strike

DiaMedica Therapeutics Inc. CFO and Secretary, Kellen Scott, was granted 162,000 stock options with an exercise price of $5.84 per share. These options, part of compensation rather than a market purchase, will vest 25% after one year and the remainder in twelve quarterly installm

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

DiaMedica Therapeutics (DMAC) director granted 40,412 stock options at $5.84

DiaMedica Therapeutics (DMAC) director Randall Michael Giuffre was granted 40,412 stock options at an exercise price of $5.84 per share. These options are for Voting Common Shares, expire on June 1, 2036, and will vest in four equal quarterly installments. This transaction was re

Tone
Positive 60/100
Event
Market update
Published
03 Jun 2026 21:39
Source
Stock Titan